Argenica Therapeutics LtdASX: AGN

FDA Feedback Received, Requests Additional Rat Study

· Issued by Argenica Therapeutics Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Argenica Therapeutics Ltd has received feedback from the FDA regarding its clinical hold on the IND for xaranetide in acute ischaemic stroke, which remains in place pending additional studies. The FDA has requested a non-clinical neurotoxicity study in rats to assess potential toxic effects before clinical dosing can commence in the US. Additionally, the FDA has revised the permitted clinical exposure limit, which the company disputes based on its own data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX ANNOUNCEMENT FDA FEEDBACK RECEIVED, REQUESTS ADDITIONAL RAT STUDY Key Points: • The US FDA has advised that the clinical hold on Argenica’s IND for xaranetide in acute ischaemic stroke remains in place, requesting an additional rat study. • The FDA has requested additional non-clinical...

Argenica Therapeutics Ltd on 6ix

Earlier from Argenica Therapeutics

Later from Argenica Therapeutics

All Argenica Therapeutics news releases